The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Painful Liver Biopsies May Be a Thing of the Past

Back to News Homepage

Next

Beyond the Liver: Milk Thistle’s 4 Extra Benefits

Zepatier Is FDA-Approved to Treat Hepatitis C

January 29, 2016

Print this page

Less costly than previously approved treatments, learn more about Merck’s newly FDA-approved Zepatier for Hepatitis C patients.

FDA OKs Merck’s Zepatier (Grazoprevir/Elbasvir) to Treat Hep C

The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir), with or without ribavirin, to treat those with genotypes 1 and 4 hepatitis C virus (HCV).

Zepatier (ZEP’-ah-teer”) includes NS3/4A protease inhibitor grazoprevir and the NS5A replication complex inhibitor elbasvir.

Continue reading this entire article:
https://www.hepmag.com/article/fda-oks-mercks-zepatier-grazoprevirelbasvir-treat-hepatitis-c

2 Comments
Share
Share

Previous

Painful Liver Biopsies May Be a Thing of the Past

Back to News Homepage

Next

Beyond the Liver: Milk Thistle’s 4 Extra Benefits

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.